Why has therapy development for dementia failed in the last two decades?
|Title||Why has therapy development for dementia failed in the last two decades?|
|Publication Type||Journal Article|
|Year of Publication||2016|
|Authors||Gauthier S, Albert M, Fox N, Goedert M, Kivipelto M, Mestre-Ferrandiz J, Middleton LT|
|Date Published||2016 Jan|
|Keywords||Alzheimer Disease, Biomarkers, Cholinesterase Inhibitors, Clinical Trials as Topic, Dementia, Drug Discovery, Humans, Memantine, Treatment Failure|
The success rate of the pharmaceutical research and development (R&D) for dementia drugs has been abysmally low, in the last two decades. Also low has been the number of pipeline drugs in development, compared to other therapy areas. However, the rationale of early terminations has not been reported in the majority of trials. These are key findings of the recently published pharmaceutical pipeline analysis by the UK-based Office of Health Economics (OHE). Our understanding of main challenges include (1) the significant gaps of knowledge in the nosology and complexity of the underpinning biological mechanisms of the commonest, not familial, forms of late onset dementias; (2) low signal-to-noise ratio, notwithstanding the lack of validated biomarkers as entry and/or end-point criteria; (3) recruitment and retention, particularly in the asymptomatic and early disease stages. A number of current and future strategies aimed at ameliorating drug development are outlined and discussed.
|Alternate Journal||Alzheimers Dement|
|Grant List||MC_U105184291 / / Medical Research Council / United Kingdom|